文献速递肝肾功能剂量调整特殊人群用药

肾功能或肝损伤不影响皮下卡格列肽的药代动力学、安全性或耐受性

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.
PubMed 文献 · Clin Pharmacokinet · 2026-06-01

卡格列肽是长效胰淀素激动剂,两项研究评估了单次皮下注射0.6或0.9 mg后肝肾功能损伤对药代动力学、安全性和耐受性的影响。结果显示,与正常功能相比,轻、中、重度肾或肝损伤患者的卡格列肽总暴露量(AUC0-∞)和Cmax均无一致模式的变化,未观察到临床相关差异,提示这些人群无需调整剂量;卡格列肽耐受性良好,无新的安全性发现。

要点

  • 轻至重度肾损伤患者卡格列肽AUC0-∞几何均值比与正常肾功能相比无临床相关差异。
  • 轻至重度肝损伤患者卡格列肽AUC0-∞几何均值比与正常肝功能相比无临床相关差异。
  • 肾或肝损伤患者无需调整卡格列肽剂量,且耐受性良好。

核心结论

  • 在样本量较小的局限性下,肾或肝损伤患者与正常功能者相比,卡格列肽药代动力学无临床相关差异,提示无需调整剂量。
  • 卡格列肽耐受性良好,未发现意外安全性问题。

研究设计与样本

  • 两项研究均将成人受试者按肾功能或肝功能分为正常功能及轻度、中度、重度损伤四组。
  • 肾功能损伤研究纳入33例受试者,单次皮下注射卡格列肽0.6 mg。
  • 肝功能损伤研究纳入32例受试者,单次皮下注射卡格列肽0.9 mg。
  • 主要终点为从第1天至第36天(肾损伤研究)或第39天(肝损伤研究)的卡格列肽血浆浓度-时间曲线下面积(AUC0-∞)。

主要发现

  • 两项研究中,卡格列肽总暴露量(AUC0-∞)、Cmax及其他药代动力学参数在各组间相似,未随肾或肝损伤严重程度呈现一致变化模式。
  • 与正常肾功能相比,轻度、中度、重度肾损伤的AUC0-∞几何均值比分别为1.23(90%CI 0.91-1.66)、1.18(0.87-1.59)、1.21(0.87-1.68)。
  • 与正常肝功能相比,轻度、中度、重度肝损伤的AUC0-∞几何均值比分别为0.99(0.89-1.11)、1.01(0.91-1.12)、1.11(0.96-1.30)。
  • 肾损伤研究11例受试者报告21例次治疗中出现的不良事件(TEAE),肝损伤研究9例受试者报告16例次TEAE。
  • 两项研究均未报告严重TEAE、导致退出研究的TEAE或死亡,不良事件数量未随肾或肝损伤严重程度增加而增加。

临床怎么用

  • 对于合并轻至重度肾功能损伤或肝功能损伤的成人患者,使用卡格列肽时无需根据肝肾功能调整剂量。
  • 用药期间仍需常规监测安全性和耐受性,尤其关注不良事件的发生。

局限性

  • 两项研究样本量较小,可能影响统计效能和结果的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes. Two studies were conducted to assess the effects of renal or hepatic impairment on pharmacokinetics, safety and tolerability following single doses of cagrilintide. METHODS: In both studies, adult participants were categorised into four groups on the basis of renal or hepatic function (normal function and mild, moderate or severe impairment) and received a single dose of cagrilintide 0.6 or 0.9 mg, respectively. The primary endpoint was area under the cagrilintide plasma concentration curve from time zero extrapolated to infinity (AUC0-∞) from baseline (day 1) to day 36 (renal impairment study) or day 39 (hepatic impairment study). Other pharmacokinetic parameters included maximum observed cagrilintide plasma concentration (Cmax), time to Cmax (tmax) and safety. RESULTS: The renal impairment study included 33 participants (normal function, n = 14; mild impairment, n = 7; moderate impairment, n = 7; severe impairment, n = 5) and the hepatic impairment study included 32 participants (normal function, n = 14; mild impairment, n = 7; moderate impairment, n = 7; severe impairment, n = 4). In both studies, total cagrilintide exposure (AUC0-∞), Cmax and other pharmacokinetic parameters were similar across groups with no consistent patterns observed with renal or hepatic impairment. Compared with normal renal function, the estimated ratio of the mean AUC0-∞ was 1.23 (90% confidence interval [CI], 0.91-1.66) in mild impairment, 1.18 (0.87-1.59) in moderate impairment and 1.21 (0.87-1.68) in severe impairment. Compared with normal hepatic function, the estimated ratio of the mean AUC0-∞ was 0.99 (0.89-1.11) in mild impairment, 1.01 (0.91-1.12) in moderate impairment and 1.11 (0.96-1.30) in severe impairment. Overall, 21 and 16 treatment-emergent adverse events (TEAEs) were reported in 11 and 9 participants in the renal and hepatic studies, respectively. In both studies, no serious TEAEs, TEAEs leading to study withdrawal or deaths were reported. No increase in number of adverse events with increasing renal or hepatic impairment was observed, and no new safety or tolerability findings with cagrilintide were identified with renal or hepatic impairment. CONCLUSIONS: In these studies, within the limitations of small sample sizes, no clinically relevant differences in cagrilintide pharmacokinetics were observed in participants with renal or hepatic impairment compared with those with normal function, suggesting that dose adjustment is not warranted for these populations. Cagrilintide was well-tolerated and there were no unexpected safety issues. TRIAL REGISTRATION: Studies are registered at ClinicalTrials.gov (NCT04209049 registered 23 December 2019 and NCT05564104 registered 3 October 2022).

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Nielsen MJF, Becker NP, Duus HHH, et al. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Clin Pharmacokinet. 2026. PMID: 42228334. doi:10.1007/s40262-026-01654-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。